Genenta Science SpA ADR (NASDAQ:GNTA) — Market Cap & Net Worth
Market Cap & Net Worth: Genenta Science SpA ADR (GNTA)
Genenta Science SpA ADR (NASDAQ:GNTA) has a market capitalization of $16.45 Million ($16.45 Million) as of May 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25606 globally and #5156 in its home market, demonstrating a -1.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genenta Science SpA ADR's stock price $0.70 by its total outstanding shares 23432183 (23.43 Million). Analyse Genenta Science SpA ADR (GNTA) cash flow conversion to see how efficiently the company converts income to cash.
Genenta Science SpA ADR Market Cap History: 2021 to 2026
Genenta Science SpA ADR's market capitalization history from 2021 to 2026. Data shows change from $256.85 Million to $17.11 Million (-46.83% CAGR).
Index Memberships
Genenta Science SpA ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #734 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2419 of 3165 |
Weight: Genenta Science SpA ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Genenta Science SpA ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genenta Science SpA ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GNTA by Market Capitalization
Companies near Genenta Science SpA ADR in the global market cap rankings as of May 3, 2026.
Key companies related to Genenta Science SpA ADR by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Genenta Science SpA ADR Historical Marketcap From 2021 to 2026
Between 2021 and today, Genenta Science SpA ADR's market cap moved from $256.85 Million to $ 17.11 Million, with a yearly change of -46.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $17.11 Million | -51.01% |
| 2025 | $34.91 Million | -65.75% |
| 2024 | $101.93 Million | -12.12% |
| 2023 | $115.99 Million | -10.00% |
| 2022 | $128.88 Million | -49.82% |
| 2021 | $256.85 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Genenta Science SpA ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $16.45 Million USD |
| MoneyControl | $16.45 Million USD |
| MarketWatch | $16.45 Million USD |
| marketcap.company | $16.45 Million USD |
| Reuters | $16.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more